Mesa Laboratories Inc 8-K, filed Oct 1, 2020
Mesa Laboratories Inc /Co/ (MLAB)
8-K
2020-10-01
For: 2020-09-28
View Original
Added on
April 11, 2026
About this 8-K
Mesa Laboratories Inc filed this 8-K on October 1, 2020, reporting on events of September 28, 2020.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction of incorporation) |
(Commission File Number)
|
(I.R.S. Employer Identification No.) |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: 303 -987-8000
Not Applicable
(Former name or former address, if changed since last report)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 28, 2020, David Perez, resigned from the Board of Directors of Mesa Laboratories, Inc., the Audit Committee of the Board, and the Compensation Committee of the Board, effective immediately. Mr. Perez indicated that his resignation is due to his expected new responsibilities as Chairman of the Board of Directors of another company. Mr. Perez’s decision to resign from the Board was not the result of a disagreement with the Company on any matter relating to its operations, policies or practices.
The Board of Directors of Mesa Laboratories, Inc. appointed Jenny Alltoft to the Audit Committee effective immediately.
As a result of the forgoing changes, the members of the Audit Committee are now as follows: Evan Guillemin (Chair), John Schmieder, and Jenny Alltoft.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
DATE: October 1, 2020
|
|
|
|
Mesa Laboratories, Inc.
(Registrant)
/s/ Gary M. Owens
BY: Gary M. Owens,
President and Chief Executive Officer |